Transdermal delivery with microneedle patches using in silico modelling by Rajoli, RKR et al.
Transdermal delivery with 
microneedle patches using in silico
modelling
Rajith KR Rajoli1, Charles Flexner2, Andrew Owen1, Ryan F. Donnelly3, Marco Siccardi1
1 Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK, 2 Johns Hopkins University, Baltimore, Maryland, 
USA, 3 School of Pharmacy, Queen’s University Belfast, Medical Biology Centre, Belfast, UK.
Abstract #2
Background
• Existing antiretroviral therapy (ART) is characterised by life-long daily 
administration
• Long-acting (LA) strategies could limit the problems associated with pill 
fatigue and sub-optimal adherence 
• Antiretrovirals are currently developed for intramuscular injectable LA 
formulations 
• Transdermal delivery through microneedle array patches represent an 
alternative strategy for LA administration 
Microneedle array patches (MAPs)
• Consist of micron-sized needle arrays of varying sizes capable of disrupting 
stratum corneum
• Capable of local and systemic delivery, blood-free with painless application
• Provide patient friendly, low cost and minimally invasive route for drug 
delivery 
• Deliver intact nanoformulations that form a depot in the upper skin layers
• Drug release from this nanoparticulate formulation is the rate limiting step 
to regulate pharmacokinetics
• Pharmacokinetics in humans was assessed using a physiologically based 
pharmacokinetic (PBPK) model
Hydrogel MAPs
Dissolving MAPs
PATH - http://www.path.org/publications/files/VAC_hiv_prep_poster.pdf
PBPK modelling
• Mathematical description of absorption, distribution, metabolism and elimination 
processes defining pharmacokinetics 
• Integrates in vitro data to simulate drug distribution in virtual population 
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Aims
• Design a transdermal PBPK model to simulate pharmacokinetics of a model drug resulting 
from administration through microneedles
• Predict pharmacokinetics of a model drug across a range of dose and release rate in 
humans to identify optimal formulation characteristics 
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P – permeability , PC – partition coefficient
PBPK model qualification for IM and transdermal formulations in 
rats in vivo
Observed Simulated
% difference*
simulated vs. 
observed
Route and dose Cmax AUC Cmin Cmax AUC Cmin Cmax AUC Cmin
Intramuscular
(5 mg/kg, single injection)1
71 3840 - 55.9 ± 6.43 5.67 ± 1.25 - -21.3 47.6 -
Intramuscular
(20 mg/kg, single injection)1
158 15300 - 222 ± 25.5 22.4 ± 4.64 - 40.5 46.3 -
Transdermal
†(120 mg, microneedle patch)2
416 - 26.5 481 ± 42.9 286 ± 28.1 38.7 ± 4.45 24.5 - 46.0
Values are represented as arithmetic mean ± standard deviation where ever applicable, AUC – area under the concentration-time curve, Cmax – maximum
plasma concentration, Ctrough – trough plasma concentration; Cmax and Ctrough are expressed as ng/ml and AUC is expressed as µg × h/ml;* PBPK model is
assumed to be qualified if % difference is less than 50, † Only 57.45 % of the total administered drug was assumed to be delivered using microneedle3
Rat in vivo
1 van ′t Klooster G, Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation.  2010 
2 Darin Zehrung, Development of microarray patches for transdermal and vaginal delivery of long-acting HIV pre-exposure prophylaxis, 2016 
3 Garland MJ et al. Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays. International Journal of Pharmaceutics. 2012;434(1):80-9.
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Transdermal release predictions – plasma concentrations
720 mg  4-weekly dose vs. various release rates (h-1)
• Ctrough increases up to a certain release rate and then decreases
• Ctrough was proportional to the increase in administered transdermal dose
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180 mg 360 mg 540 mg 720 mg 900 mg 1080 mg
PAIC95 (12 ng/ml) 10 mg PO Ctrough (70 ng/ml)
25 mg PO Ctrough
Ctrough at the end of two 4-weekly doses
Target Ctrough25 mg PO CtroughTarget Ctrough
Transdermal predictions – Ctrough vs. penetration depth, pore radius
Pharmacokinetic summary at various needle lengths
• Constant dose – 720 mg, constant release rate – 0.0015 h-1
• No significant difference observed in Ctrough (P > 0.05)
Constant pore size – 224 µm1
Pharmacokinetic summary at various pore radii
Constant needle length – 429.66 µm1
1 Garland MJ et al. Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays. International Journal of Pharmaceutics. 2012;434(1):80-9.
Limitations
• Immune response at the site of administration could alter the release rate 
• Evaluation of long-term drug and excipients stability at the administration 
site is pivotal
• Modelled formulation release rate cannot be directly extrapolated to release 
rate in vivo
• Further qualification against transdermal PK from human data would improve 
the confidence of the PBPK model
Summary
• Transdermal delivery represents an attractive, minimally invasive and effective 
route for long-acting ART administration
• Design of the transdermal PBPK model was successfully qualified against observed 
data in rats
• Dose and release rate was optimised for a model drug for a monthly transdermal 
MAPs
• Transdermal PBPK model is a platform to rationalise selection of drug candidates 
for LA therapy using MAPs
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